Search results for "Fibrin"

showing 10 items of 508 documents

Laboratory testing in the emergency department: an Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and Academy of Em…

2018

Abstract Background: The mainstay of patient-oriented laboratory testing in emergency settings entails selecting a number and the type of tests according to valid criteria of appropriateness. Since the pattern of urgent tests requesting is variable across different institutions, we designed a joined survey between the Academy of Emergency Medicine and Care (AcEMC) and the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) for reaching tentative consensus about the most informative diagnostic tests in emergency settings. Methods: A survey, containing the most commonly ordered urgent laboratory tests and the relative clinical indications, was disseminated to eigh…

medicine.medical_specialty030213 general clinical medicineConsensusClinical BiochemistryMEDLINE030204 cardiovascular system & hematologyLaboratory testingClinical biochemistryLaboratory testingFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineReference ValuesSurveys and QuestionnairesmedicineHumansNational levelConsensus documentCreatine KinaseSocieties Medicallcsh:R5-920business.industryClinical Laboratory TechniquesSettore BIO/12Mean valueBiochemistry (medical)Diagnostic testEmergency departmentUrgent testingVenous ThromboembolismGeneral MedicineReference valuesFamily medicineconsensus document; emergency medicine; laboratory testing; urgent testingEmergency medicineEmergency medicineWounds and Injuriesbusinesslcsh:Medicine (General)Emergency Service HospitalClinical Chemistry and Laboratory Medicine (CCLM)
researchProduct

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

2021

Abstract Aims Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV) events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism. Recently, two large randomized clinical trials evaluated the efficacy and safety of low-dose rivaroxaban twice daily plus aspirin in stable PAD outpatients and those immediately after peripheral revascularization. We sought to determine if the effects of low-dose rivaroxaban and aspirin compared to aspirin alone are consistent across this broad spectrum of PAD patients. Methods and results We conducted a random-effects meta-analysis of the COMPASS and VOYAGER randomized trials among 11 560 PAD patients (4996…

medicine.medical_specialtyAcute limb ischaemiaEpidemiologymedicine.medical_treatmentHemorrhageRevascularizationlaw.inventionBrain IschemiaPeripheral Arterial DiseaseRandomized controlled trialFibrinolytic AgentsRivaroxabanlawIschemiaInternal medicineMedicineHumansMyocardial infarctionAspirinRivaroxabanAspirinbusiness.industryHazard ratiomedicine.diseaseStrokeAmputationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsEuropean journal of preventive cardiology
researchProduct

Effects of soy isoflavones on endothelial function in healthy postmenopausal women.

2005

Objective: To evaluate the effects of soy isoflavone administration on endothelial function in healthy postmenopausal women. Design: Sixty naturally postmenopausal women were randomly assigned to receive isoflavone or placebo tablets for 6 months. Endothelium-dependent vasodilatation was measured by brachial reactivity technique along with levels of plasma soluble intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, P-selectin and soluble thrombomodulin, von Willebrand factor, and tissue plasminogen activator. Differences between endothelium-dependent and endothelium-independent vasodilatation were assessed by evaluating brachial reactivity par…

medicine.medical_specialtyAdhesion moleculeEndotheliumBrachial ArteryGenisteinVascular Cell Adhesion Molecule-1PhytoestrogensFibrinogenAdhesion molecule; Endothelial function; Postmenopausal womenchemistry.chemical_compoundVon Willebrand factorInternal medicineMedicineHumansProspective StudiesReactive hyperemiabiologybusiness.industryObstetrics and GynecologyEndothelial functionIsoflavonesMiddle AgedIntercellular Adhesion Molecule-1Postmenopausal womenIsoflavoneGenisteinIsoflavonesDietPostmenopauseVasodilationProspective StudieP-SelectinEndocrinologymedicine.anatomical_structurechemistryPhytoestrogencardiovascular systembiology.proteinFemaleEndothelium VascularSoybeansSoybeanbusinessE-SelectinPlasminogen activatorHumanLipoproteinmedicine.drugMenopause (New York, N.Y.)
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct

Effect of uric acid in animal models of ischemic stroke: A systematic review and meta-analysis

2020

Addition of uric acid (UA) to thrombolytic therapy, although safe, showed limited efficacy in improving patients’ stroke outcome, despite alleged neuroprotective effects of UA in preclinical research. This systematic review assessed the effects of UA on brain structural and functional outcomes in animal models of ischemic stroke. We searched Medline, Embase and Web of Science to identify 16 and 14 eligible rodent studies for qualitative and quantitative synthesis, respectively. Range of evidence met 10 of a possible 13 STAIR criteria. Median (Q1, Q3) quality score was 7.5 (6, 10) on the CAMARADES 15-item checklist. For each outcome, we used standardised mean difference (SMD) as effect size…

medicine.medical_specialtyBrain damageNeuroprotectionMice03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAnimal modelFibrinolytic AgentsInternal medicineStroke outcomeIschaemic strokeAnimalsHumansMedicineThrombolytic TherapyReview ArticlesIschemic Stroke030304 developmental biology0303 health sciencesbusiness.industryRecovery of FunctionRatsUric AcidNeurologychemistryMeta-analysisIschemic strokeCardiologyUric acidNeurology (clinical)Nervous System Diseasesmedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism.

2020

AbstractAimsCatheter-directed treatment of acute pulmonary embolism (PE) is technically advancing. Recent guidelines acknowledge this treatment option for patients with overt or imminent haemodynamic decompensation, particularly when systemic thrombolysis is contraindicated. We investigated patients with PE who underwent catheter-directed thrombolysis (CDT) in the German nationwide inpatient cohort.Methods and resultsData from hospitalizations with PE (International Classification of Disease code I26) between 2005 and 2016 were collected by the Federal Office of Statistics in Germany. Patients with PE who underwent CDT (OPS 8-838.60 or OPS code 8-83b.j) were compared with patients receiving…

medicine.medical_specialtyCathetersTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineLower risk03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicineMedicineHumansDecompensationThrombolytic Therapy030212 general & internal medicineProspective StudiesRetrospective Studiesbusiness.industryMortality rateGeneral MedicineOdds ratioThrombolysismedicine.diseaseHospitalsPulmonary embolismTreatment OutcomeCohortCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentEuropean heart journal. Acute cardiovascular care
researchProduct

An Evaluation of Fibrin(ogen) Determinants of Thromboelastography

2011

Abstract Abstract 2251 Thromboelastography (TEG) was used in ∼200 studies published in 2009, is mainly used for global blood coagulation assessment, and is thrombin and fibrinogen concentration-dependent. Reflecting the time course of fibrin polymerization, TEG measures lag time, rate, and maximum amplitude (MA) of clot stiffness, and is substantially enhanced by platelets. To identify more specific fibrin(ogen) determinants potentially relevant to interpretation we investigated MA under different TEG conditions. The procedure utilizes a polymethylmethacrylate (hydrophobic surface) cup and pin set, the cup oscillating through 4° 45' (6 cycles/minute). The pin (sensor) is suspended via a tor…

medicine.medical_specialtyChromatographybiologyChemistryImmunologyCell BiologyHematologyClot retractionFibrinogenFactor XIIIBiochemistryBlood proteinsFibrinSurgeryThrombinbiology.proteinmedicinePlateletFactor XIIIamedicine.drugBlood
researchProduct

Ver�nderungen an Proteinen der Leber und des Blutes bei experimenteller Lebercirrhose und nach Behandlung mit Decortin und einem anabolen Steroid

1963

medicine.medical_specialtyCirrhosisbiologyChemistrymedicine.medical_treatmentGeneral MedicineMitochondrionmedicine.diseaseFibrinogenMolecular medicineBlood proteinsEndocrinologyNandroloneInternal medicineDrug Discoverymedicinebiology.proteinMolecular MedicineCeruloplasminGenetics (clinical)Anabolic steroidmedicine.drugKlinische Wochenschrift
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct

Platelet-rich fibrin for wound healing of palatal donor sites of free gingival grafts: Systematic review and meta-analysis.

2020

Made available in DSpace on 2021-06-25T10:22:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-01-01 Background: Platelet-rich fibrin (PRF) has been referred to as a second-generation platelet concentrate, associated with improvements on the healing of palatal wounds followed by FGG harvesting. The aim of this systematic review and meta-analysis was to assess the complete wound epithelialization and postoperative pain when PRF was used in palatal wounds following free gingival graft (FGG) harvesting. Material and Methods: PubMed (Medline), EMBASE and Scopus were searched by two independent individuals up to and including March 2020 in order to identify controlled and randomized cont…

medicine.medical_specialtyCochrane collaborationbiologybusiness.industryOral surgeryWound healingReviewFibrinPlatelet-rich fibrinSurgeryClinical trialoral surgery proceduresMeta-analysisbiology.proteinpostoperativeMedicinepainPeriodontologyPlatelet concentratebusinessWound healingGeneral DentistryUNESCO:CIENCIAS MÉDICASJournal of clinical and experimental dentistry
researchProduct